Interventional coronary reperfusion strategies are widely adopted to treat acute myocardial
infarction, but morbidity and mortality of acute myocardial infarction are still high …

The intracellular sensing protein termed NLRP3 (for NACHT, LRR, and PYD domains-
containing protein 3) forms a macromolecular structure called the NLRP3 inflammasome …

Abstract Sodium-glucose-cotransporter 2 inhibitors (SGLT2is) demonstrate large
cardiovascular benefit in both diabetic and non-diabetic, acute and chronic heart failure …

Acute myocardial infarction (AMI) and the heart failure (HF) that often follows are among the
leading causes of death and disability worldwide. As such, new treatments are needed to …

Preeclampsia is a complex cardiovascular disorder of pregnancy with underlying
multifactorial pathogeneses; however, its etiology is not fully understood. It is characterized …

Sodium glucose cotransporter 2 inhibitors (SGLT2i) constitute a promising drug treatment for
heart failure patients with either preserved or reduced ejection fraction. Whereas SGLT2i …

Acute myocardial infarction causes lethal injury to cardiomyocytes during both ischaemia
and reperfusion (IR). It is important to define the precise mechanisms by which they die in …

Neutrophil extracellular traps (NETs) are formed by decondensed chromatin, histones, and
neutrophil granular proteins and have a role in entrapping microbial pathogens. NETs …

In the setting of myocardial infarction (MI), ischemia reperfusion injury (IRI) occurs due to
occlusion (ischemia) and subsequent re-establishment of blood flow (reperfusion) of a …

New therapies are required to reduce myocardial infarct (MI) size and prevent the onset of
heart failure in patients presenting with acute myocardial infarction (AMI), one of the leading …